Fractyl Health gets two new U.S. patents for duodenal resurfacing, portfolio now 31 granted patents

FRACTYL HEALTH, INC.

U.S. Patent No. 12,329,439 (June 17, 2025) and No. 12,303,185 (May 20, 2025) cover thermal and non-thermal electrical energy ablation of duodenal mucosa.
Total IP estate: 31 granted U.S. patents and ~40 pending applications, built since 2011.
Revita next milestones: REVEAL-1 open-label data June 2025, REMAIN-1 midpoint Q3 2025, primary endpoint H2 2026.
Patents reinforce Fractyl's leadership in gut-targeted metabolic therapies for obesity and type 2 diabetes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.